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Abstract
Background:  Interferon has been widely used in the treatment of genital warts for its immunomodulatory,
antiproliferative and antiviral properties. Currently, no evidence that interferon improves the complete response rate or
reduces the recurrence rate of genital warts has been generally provided. The aim of this review is to assess, from
randomized control trials (RCTs), the efficacy and safety of interferon in curing genital warts.
Methods: We searched Cochrane Sexually Transmitted Diseases Group's Trials Register (January, 2009), Cochrane
Central Register of Controlled Trials (2009, issue 1), PubMed (1950-2009), EMBASE (1974-2009), Chinese Biomedical
Literature Database (CBM) (1975-2009), China National Knowledge Infrastructure (CNKI) (1979-2009), VIP database
(1989-2009), as well as reference lists of relevant studies. Two reviewers independently screened searched studies,
extracted data and evaluated their methodological qualities. RevMan 4.2.8 software was used for meta-analysis
Results: 12 RCTs involving 1445 people were included. Among them, 7 studies demonstrated the complete response
rate of locally-used interferon as compared to placebo for treating genital warts. Based on meta-analysis, the rate of
Complete response of the two interventions differed significantly (locally-used interferon:44.4%; placebo:16.1%). The
difference between the two groups had statistical significance (RR 2.68, 95% CI 1.79 to 4.02, P < 0.00001). 5 studies
demonstrated the complete response rate of systemically-used interferon as compared to placebo for treating genital
warts. Based on meta-analysis, the rate of Complete response of the two interventions had no perceivable discrepancy
(systemically-used interferon:27.4%; placebo:26.4%). The difference between the two groups had no statistical
significance (RR1.25, 95% CI 0.80 to 1.95, P > 0.05). 7 studies demonstrated the recurrence rate of interferon as
compared to placebo for treating genital warts. Based on meta-analysis, the recurrence rate of the two interventions had
no perceivable discrepancy(interferon 21.1%; placebo: 34.2%). The difference between the two groups had no statistical
significance (RR0.56, 95% CI 0.27 to 1.18, P > 0.05). However, subgroup analysis showed that HPV-infected patients with
locally administered interferon were less likely than those given placebo to relapse, but that no significant difference in
relapse rates was observed between systemic and placebo. The reported adverse events of interferon were mostly mild
and transient, which could be well tolerated.
Conclusion:  Interferon tends to be a fairly well-tolerated form of therapy. According to different routes of
administration, locally-used interferon appears to be much more effective than both systemically-used interferon and
placebo in either improving the complete response rate or reducing the recurrence rate for the treatment of genital
warts.
Published: 21 September 2009
BMC Infectious Diseases 2009, 9:156 doi:10.1186/1471-2334-9-156
Received: 12 March 2009
Accepted: 21 September 2009
This article is available from: http://www.biomedcentral.com/1471-2334/9/156
© 2009 Yang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Infectious Diseases 2009, 9:156 http://www.biomedcentral.com/1471-2334/9/156
Page 2 of 9
(page number not for citation purposes)
Background
Description of the condition
Genital warts, which are also called condylomata acumi-
nata or venereal warts, are the most common sexually
transmitted disease (STD) in the general population[1].
The incidence of it is increasing rapidly and closely related
human papillomaviruses(HPV) have been associated inti-
mately with cervical neoplasia and other genital tract neo-
plasms [2-6]. It is estimated that 1% of sexually active
people between the ages of 18 and 45 have genital warts.
However, polymerase chain reaction (PCR) testing indi-
cates that as many as 40% of sexually active adults carry
HPV that causes genital warts. Genital warts are very con-
tagious and could be spread during oral, genital, or anal
sex with an infected partner. About two-thirds of people
who have sexual contact with a partner with genital warts
will develop warts, usually within three months of con-
tact[7].
Genital warts vary somewhat in appearance. They may be
either flat or resemble raspberries or cauliflower. The
warts begin as small red or pink growths and grow as large
as four inches across, interfering with intercourse and
childbirth(in some cases). The warts grow in the moist tis-
sues of the genital areas. In women, they occur on the
external genitals and on the walls of the vagina and cervix;
in men, they develop in the urethra and on the shaft of the
penis.
Current treatment for genital warts is less than satisfying.
No clear ideal therapy has been identified. Locally
destruction methods, have mainly included surgical exci-
sion, electrocautery, cryosurgery and laser vaporization,
which may result in scarring and are associated with recur-
rence. Chemical destructive methods using various acids,
such as trichloroacetic or bichloroacetic acid, can be
applied by the patients but are often locally irritating and
not uniformly effective. Podophyllum resin, Podophyllo-
toxin, immune inducers (e.g., imiquimod), 5-fluorouracil
cream can be used as a topical treatment. However, these
medications require several weeks of treatment and may
also irritate the skin [8-11].
Decription of the intervention
In human body, Interferons are a class of small (15-28
kD) protein and glycoprotein cytokines (15-28 kD) pro-
duced by T cells, fibroblasts, and other cells in response to
viral infection and other biologic and synthetic stimuli.
IFNs bind to specific receptors on cell membranes. Their
effects include inducing enzymes, suppressing cell prolif-
eration, inhibiting viral proliferation, enhancing the
phagocytic activity of macrophages, and augmenting the
cytotoxic activity of T lymphocytes. As a curative drug,
Interferon could be divided into three major classes
(alpha, beta, gamma) on the basis of physicochemical
properties, cells of origin, mode of induction, and anti-
body reactions[12].
Interferon has been shown to be active against HPV both
in vitro and in vivo, to protect murine cells against infec-
tion with bovine papillomaviruses and to eliminate extra-
chromosomal viral DNA from infected cells [12,13]. The
chief mechanism of its potential efficacy probably consists
of following three fronts: (1) It acts as an antiviral agent;
(2) it has an antiproliferative effect; and (3) it elicits an
immune response from the host [13-16]. Based on these
properties, interferon may lead to encouraging effects in
the treatment of genital warts. It is reported that interfer-
ons exert their activities mainly by binding to specific
membrane receptors on the cell surface. Once bound to
the cell membrane, interferons initiate a complex
sequence of intracellular events. In vitro studies demon-
strated that these include the induction of certain
enzymes, suppression of cell proliferation, immunomod-
ulating activities such as enhancement of the phagocytic
activity of macrophages and augmentation of the specific
cytotoxicity of lymphocytes for target cells, and inhibition
of virus replication in virus-infected cells.
By and large, interferon could be used either locally or sys-
temically. Local administrations are mainly composed of
intralesional injections and topical applications, in con-
trast to systemic administrations comprising subcutane-
ous and intramuscular injections.
Why it is important to do this review
Due to the uncertainty of findings from current studies,
what is more, HPV-infected patients must be provided
with available information with which to make informed
decisions regarding what kind of therapy for genital warts
is relatively more effective, we aim to determine if there is
any evidence from randomized controlled trials (RCTs)
that the administration of interferon is efficacious for the
treatment of genital warts.
Methods
Criteria for considering studies for this review
Types of studies
We included RCTs only.
Types of participants
HPV-infected patients. who were clinically or experimen-
tally diagnosed as genital warts, were participated into our
study.
Types of intervention
Interferon versus placebo. Interferon could be used either
locally or systemically.BMC Infectious Diseases 2009, 9:156 http://www.biomedcentral.com/1471-2334/9/156
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Types of outcome measures
Primary outcomes
Complete response rate and recurrence rate.
Secondary outcomes
Adverse effects such as flu-like symptoms(fever, chill,
headache, myalgias, fatigue, etc), depression, anaemia,
leukopenia, thrombocytopenia and so on.
Search methods for identification of studies
Electronic searches
We searched the electronic databases as follows: Cochrane
Sexually Transmitted Diseases Group's Trials Register
(January, 2009), Cochrane Central Register of Controlled
Trials (the Cochrane Library 2009, issue 1), PubMed
(1950 to 2009), EMBASE (1974 to 2009), Chinese Bio-
medical Literature Database (CBM) (1975 to 2009),
China National Knowledge Infrastructure (CNKI) (1979
to 2009), VIP database (1989 to 2009). We also searched
additional trials by scanning the reference lists of relevant
trials identified. The search strategy was iterative as fol-
lows:
1 HPV
2 GENITAL WARTS
3 CONDYLOMATA ACUMINATA
4 VENEREAL WARTS
5 #2 OR #3 OR #4
6 INTERFERON
7 #1 AND #5 AND #6
8 (ANIMAL OR ANIMALS) NOT HUMAN
9 #7 NOT #8
Other search strategies
Organizations (including the World Health Organiza-
tion), individual researchers working in the field were
contacted in order to obtain possible additional refer-
ences, unpublished trials, or ongoing trials, confidential
reports and raw data of published trials.
Selection of studies
The titles, abstracts and keywords of every record retrieved
were scanned to determine which were possibly relevant
to the review. Any record that appeared likely to meet the
inclusion criteria was obtained in full text. If there was any
doubt regarding eligibility from the information given in
the title and abstract, the full article was retrieved for clar-
ification. Differences in opinion between reviewers were
resolved by discussion.
Data extraction
Two review authors independently extracted data con-
cerning details of the study population, interventions and
outcomes using a standard data extraction form, specifi-
cally designed for this review. We resolved differences in
data extraction by consensus, and with reference to the
original article. If necessary, we sought information from
the authors of the primary studies. For dichotomous out-
comes, number of events and total number in each group
were extracted. For continuous outcomes, mean, standard
deviation and sample size of each group were extracted.
Assessment of risk of bias in included trials
The risk of bias was assessed based largely on the quality
criteria specified by the Cochrane Handbook for System-
atic Reviews of Interventions 5.0.1 [17]. In particular, the
following factors were studied:
￿ Selection bias: a) was the randomization procedure ade-
quate? b) was the allocation concealment adequate?
￿ Performance bias: were the patients and people per-
forming the intervention blind to the intervention?
￿ Attrition bias: a) were withdrawals, dropouts and losses
of follow-up completely described? b) was analysis per-
formed by intention-to-treat?
￿ Detection bias: were outcome assessors blind to the
intervention?
Based on these criteria, studies were broadly divided into
the following three categories. This classification was used
as the basis of a sensitivity analysis. Additionally, we
intended to explore the influence of individual quality cri-
teria in a sensitivity analysis.
￿ A: all quality criteria met - low risk of bias.
￿ B: one or more of the quality criteria only partly met -
moderate risk of bias.
￿ C: one or more criteria not met - high risk of bias.
Each trial was assessed by two reviewers independently.
Disagreements were resolved, where necessary, by
recourse to a third reviewer. In cases of disagreement, the
rest of the group were consulted and a judgment was
made based on consensus.BMC Infectious Diseases 2009, 9:156 http://www.biomedcentral.com/1471-2334/9/156
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Data Analysis
Statistical analysis was carried out by using Review Man-
ager (version 4.2). Dichotomous data were presented as
relative risk (RR) and continuous outcomes as weighted
mean difference (WMD), both with 95% confidence
intervals (CI). The overall effect was tested by using Z
score with significance being set at P < 0.05. Heterogeneity
was tested by using the chi-squared statistic and I square
(I2) with significance being set at P < 0.1. Possible sources
of heterogeneity were to be assessed by sensitivity and
subgroup analyses. A fixed-effect model was to be used
when the studies in the subgroup were sufficiently similar
(P > 0.10, I2 < 50%). A random effects model was to be
used in the summary analysis when there was heterogene-
ity between the subgroups. Publication bias was to be
tested by using the funnel plot or other corrective analyti-
cal method, depending on the number of clinical trials
included in the systematic review.
Results
Description of studies
Studies identified
Our initial searches identified 1074 studies. No unpub-
lished studies or other information was obtained from
contact with WHO and individual researchers. By scan-
ning titles and abstracts, 995 of them were excluded
because they were duplicates, non-clinical studies, or had
study objectives different from this review. After referring
to full texts, 67 were excluded upon further scrutiny due
to the following reasons: 42 studies were not real RCTs(of
the 42 studies,17 were only case record analyses, and 25
did not develop a protocol before recruiting partici-
pants);16 studies had other interventions potentially
impacting the outcome; 9 study had follow-up duration
less than three months after the end of intervention with
interferon. Finally, we included 12 studies, which
involved a total of 1445 patients. Among them, 11 were
published in English [18-28], 1 in Chinese(available only
by searching the database of CNKI). Apart from Chinese
and English, we did not search citations in other lan-
guages.
Designs of included studies
All the included studies were of a parallel design and had
a control group.
Participants of included studies
Numbers of participants of the individual studies ranged
from 42 to 257 with a total of 1445 participants included
in this review. All of them were HPV-infected patients
who were clinically or experimentally diagnosed as genital
warts. The baseline characteristics (including the sex, age,
race, mean lesion areas at study entry, median number of
warts per patient, duration of diseases before therapy, and
severity of disease, etc) were similar in the two groups (P
> 0.05).
Interventions of included studies
Interferon used either locally or systemically was made as
the intervention group, and placebo as the control group
in each of the twelve studies.
Outcomes of included studies
The common outcome reported was the complete
response rate and adverse events. However, of 12 included
studies, only 7 reported recurrence rate.
Methodological quality
Randomization
All the included studies were randomized controlled tri-
als. Among them, 3 studies carried out the randomized
assignment according to the randomization sequences
generated by computer software.
Allocation concealment
Of 12 included studies, 1 study used sealed and opaque
envelope to conceal the allocation process.
Blinding
Double blind was used in each included study. But there
is lack of outcome assessor blinding.
Description of withdrawals, dropouts, losses of follow up and 
intention-to-treat analysis
2 of the included studies gave a description of losses of
follow up and performed intention-to-treat analyses. 7
studies described withdrawals, dropouts or losses of fol-
low up, but did not perform any intention-to-treat analy-
sis. Other 3 studies did not describe any of them.
According to the quality criteria listed above, we consid-
ered all included studies were at moderate risk of bias and
graded as category B
Effects of interventions
Assessment of the Complete response rate of locally-used interferon 
versus placebo for treating genital warts
7 studies demonstrated the complete response rate of
locally-used interferon (intralesional interferon or gel
interferon) as compared to placebo for treating genital
warts. According to chi-squared statistic and I square (I2),
the results of the seven studies showed apparent statistical
heterogeneity (p = 0.04.I2 = 54.3%). So we used random
effects model for meta-analysis. After synthesizing the
results, we found out that the rate of Complete response
of the two interventions differed significantly (locally-
used interferon 44.4%; placebo: 16.1%). The difference
between the two groups had statistical significance
(RR2.68, 95% CI 1.79 to 4.02, P < 0.00001) (Figure 1).BMC Infectious Diseases 2009, 9:156 http://www.biomedcentral.com/1471-2334/9/156
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Assessment of the Complete response rate of systemically-used 
interferon versus placebo for treating genital warts
5 studies demonstrated the complete response rate of sys-
temically-used interferon as compared to placebo for
treating genital warts. According to chi-squared statistic
and I square (I2), the results of the 5 studies also showed
apparent statistical heterogeneity (p = 0.06.I2 = 55.5%). So
we used random effects model for meta-analysis. After
synthesizing the results, we found out that the rate of
Complete response of the two interventions had no per-
ceivable discrepancy (systemically-used interferon 27.4%;
placebo: 26.4%). The difference between the two groups
had no statistical significance (RR1.25, 95% CI 0.80 to
1.95, P > 0.05) (Figure 2).
Assessment of the recurrence rate of interferon versus placebo for 
treating genital warts
7 studies demonstrated the recurrence rate of interferon as
compared to placebo for treating genital warts. According
to chi-squared statistic and I square (I2), the results of the
7 studies also showed apparent statistical heterogeneity (p
= 0.08.I2 = 47.1%). So we used random effects model for
meta-analysis. After synthesizing the results, we found out
that the recurrence rate of the two interventions also had
no perceivable discrepancy(interferon 21.1%; placebo:
34.2%). The difference between the two groups had no
statistical significance (RR0.56, 95% CI 0.27 to 1.18, P >
0.05) (Figure 3).
Analysis of the Complete response rate of locally-used interferon versus placebo for treating genital warts Figure 1
Analysis of the Complete response rate of locally-used interferon versus placebo for treating genital warts.
Analysis of the Complete response rate of systemically-used interferon versus placebo for treating genital warts Figure 2
Analysis of the Complete response rate of systemically-used interferon versus placebo for treating genital 
warts.BMC Infectious Diseases 2009, 9:156 http://www.biomedcentral.com/1471-2334/9/156
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Subgroup analyses
Of the 7 included studies that reported recurrence rate of
interferon as compared to placebo for treating genital
warts, 4 trials treated patients with locally-used interferon
while 3 trails with systemically-used interferon. So sub-
group analysis was carried out under the two circum-
stances. Results showed that the trend towards decreased
recurrence rate of systemically-used interferon group com-
pared to placebo group(RR 0.72, 95% CI 0.24 to 2.18)
was lower than that of locally-used interferon group com-
pared to placebo group(RR 0.57, 95% CI 0.38 to 0.88)
(Figure 4).
Sensitivity analyses
We did not carry out any of the planned sensitivity analy-
ses as no unpublished studies were found and all included
studies were at similar risk of bias.
Analysis of the recurrence rate of interferon versus placebo for treating genital warts Figure 3
Analysis of the recurrence rate of interferon versus placebo for treating genital warts.
Subgroup analysis of the recurrence rate of interferon versus placebo for treating genital warts Figure 4
Subgroup analysis of the recurrence rate of interferon versus placebo for treating genital warts.BMC Infectious Diseases 2009, 9:156 http://www.biomedcentral.com/1471-2334/9/156
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Assessment of publication bias
There was an insufficient number of trials for us to assess
publication bias.
Adverse events
All included studies had reported the adverse events of
interferon. The most common reported adverse reaction
of systemic interferon was a flu-like syndrome, which was
defined as the simultaneous occurrence of two of the fol-
lowing: fever/chills, headache, malaise/fatigue, and myal-
gia/muscle aches. Usually these flu-like syndromes were
mild to moderate and decreased in incidence with
repeated administration of interferon. Application-site
reactions, such as itching, burning sensation and pain,
occurred in parts of patients treated with intralesional
interferon. In some trials, analysis of laboratory values
obtained during and after systemic interferon therapy ver-
sus placebo revealed decrease in white-cell and platelet
counts (leukopenia, thrombocytopenia). However, these
values all returned to normal after the end of the treat-
ment. There were no significant differences between the
two groups in the results of liver-function tests (levels of
serum aspartate aminotransferase, alanine aminotrans-
ferase) or in blood urea nitrogen or creatinine levels.
Discussion
Analysis of the effect of interferon for the treatment of 
genital warts
The immune status of the host is fairly crucial in the natu-
ral history of wart growth. This could be confirmed by the
20-30% rate of spontaneous remission during the first
year of infection among otherwise healthy patients, and,
on the other hand by the extensive refractory disease
observed among immunosuppressed patients [28,29].
Conventional treatments for genital warts, including
physical or chemical ablation of warts, may cause local
issues such as inflammation, pain, ulceration or scars
[30]. In addition, these methods only destroy visible
lesions, but HPV may persist in normal-appearing epithe-
lium adjacent to treated lesions, which results in a high
rate of recurrences[8,31-33]. To the contrary, by way of its
immunomodulating effect, interferon probably derives
from its capacity to eradicate the virus from all the affected
cells. For example, a T-helper lymphocyte deficiency, asso-
ciated to an inversion of T4/T8 ratio has been observed in
condylomatous lesions, with improvement of these con-
ditions after interferon therapy[34].
In view of our study, 12 clinical trails were identified
which evaluated the efficacy of interferon for the treat-
ment of genital warts. As to complete response rate, they
indicated locally-used interferon could achieve a clear
beneficial effect while systemically-used interferon could
not, both as compared to placebo. With regard to recur-
rence rate, interferon group appeared to show no lower
recurrence rate than placebo group. However, by evaluat-
ing the included materials, we discovered that heterogene-
ity existed between the two groups. Hence, sub-group
analysis was carried out under the two circumstances. The
results demonstrated that HPV-infected patients with
locally administered interferon were less likely than those
given placebo to relapse, but that no significant difference
in relapse rates was observed between systemic and pla-
cebo. As far as safety is concerned, interferon was not toxic
and well tolerated, with a relatively low incidence of sys-
temic adverse events, which were mild and did not require
treatment interruption. In addition, one trial evaluated
the different effects among three intralesional interferon
preparations for treating genital warts, indicating that
recipients of alpha-n1-, beta-, and alpha-2b-interferons
had similar rates of complete resolution of lesions,
although the member of patients enrolled in the study did
not provide sufficient power to detect small but statisti-
cally significant differences among the different interferon
preparations. In summary, there are at least two possible
explanations for our observation that locally-used inter-
feron could be more effective and achieve better long-last-
ing effects than systemically-used interferon. Because
genital warts is widely regarded as a local illness, it is prob-
able that warts are more sensitive to local administration,
optimizing suppression of viral replication and cellular
proliferation. Also, systemic administration of interferon
may result in much lower intralesional effects of inter-
feron. Thereby, locally-used interferon (intralesional
injections or topical applications) are more worthy of rec-
ommendation than both systemically-used interferon
(subcutaneous or intramuscular injections) and placebo
for the treatment of genital warts.
Care should be taken, because both clearance rates and
recurrence rates were measured at different times from the
start of treatment in the 12 included trials(e.g.,4,8,16
weeks from baseline or different time duration from ini-
tial clearance). This may potentially influence the result of
this review. However, currently, no standard time scales
are available to measure clearance rate and recurrence rate
in the treatment of genital warts. So it is difficult for us to
make a proper inclusion criteria in study design. We
believe that this point has also been considered by the
authors of clinical trials. In light of it, we are expecting fur-
ther research should provide standard time scales to better
evaluate the clearance rate and recurrence rate of inter-
feron therapy for genital warts.
Limitations of this systematic review
Of 12 retrieved studies, only 3 trails describe randomiza-
tion procedure. Other 9 did not give adequate descrip-
tions of the methodology used. This may have misled us
if we had not clarified the details, identifying the trials
into category B rather than C. Allocation concealment isBMC Infectious Diseases 2009, 9:156 http://www.biomedcentral.com/1471-2334/9/156
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an important marker of trial quality. In a study of 250
controlled trials from 33 meta-analyses in pregnancy and
childbirth, investigators found that alleged RCTs with
inadequate and unclear allocation concealment yielded
larger estimates of treatment effects (41% and 33%,
respectively, on average)than trials in which authors
reported adequate concealment[35]. However, very few
potential articles considered for our review reported or
performed allocation concealment, leading to high risk of
selection bias.
Over and above, none of the studies mentioned blinding
to the outcome assessors, which promotes suspicion of
detection bias. In addition, 2 of the included studies gave
a description of losses of follow up and performed inten-
tion-to-treat analyses. 7 studies described withdrawals,
dropouts or losses of follow up, but did not perform any
intention-to-treat analysis. Other 3 studies did not
describe any of them. This may have led to relatively high
attrition bias in our study. Otherwise, publication bias
may exist as no primary articles reporting negative results
were found.
Implications for future researches
More high quality randomized controlled trials are
required for assessing the effects of interferon for the treat-
ment of genital warts. Especially, the randomization pro-
cedure should be clearly described, allocation
concealment should be emphasized and the approaches
should be reported. Besides, we expect that further
detailed conducted, placebo-controlled studies of
parenterally administered interferons should be carried
out to examine the effects of different routes of adminis-
tration, and more attention should be paid to combined
treatment with interferon and other therapeutic agents on
rates of regression and recurrence of genital warts.
Conclusion
Interferon tends to be a fairly well-tolerated form of ther-
apy. According to different routes of administration,
locally-used interferon appears to be much more effective
than both systemically-used interferon and placebo in
either improving the complete response rate or reducing
the recurrence rate for the treatment of genital warts.
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